Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to report that it has released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results in a press release dated October 28, 2025, which is included as Exhibit 99.1. This filing mainly serves to formally furnish that earnings press release to investors and regulators.
Kiniksa Pharmaceuticals International, plc (KNSA) disclosed insider transactions by its Chairman & CEO under a Rule 10b5-1 plan. On 10/20–10/22/2025, the insider exercised 257,969 share options at $3.80 and sold an equal 257,969 Class A Ordinary Shares in brokered trades.
Weighted average sale prices reported include $38.81 (range $38.14–$39.135), $39.32 (range $39.14–$39.55), $38.77 (range $38.49–$39.235), and $38.83 (range $38.495–$39.255). Following these transactions, direct holdings were 111,794 shares. An additional 109,795 shares were held indirectly by The Marina 2016 Irrevocable Trust.
Kiniksa Pharmaceuticals (KNSA) insider transaction: The company’s Chief Accounting Officer exercised multiple vested stock options and sold shares on 10/20/2025 pursuant to a Rule 10b5-1 plan executed on May 24, 2025. Option exercises added 791 shares at $15.50, 6,195 at $12.97, 9,831 at $11.10, 9,831 at $11.97, and 12,787 at $10.76.
The insider then sold 37,255 shares at a weighted average price of $38.72 (trades ranged from $38.14 to $39.135) and 13,235 shares at a weighted average price of $39.31 (trades ranged from $39.145 to $39.57). After these transactions, the insider beneficially owned 27,046 Class A ordinary shares, held directly. The filing notes the options were fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) reported a Form 4 for its COO. On 10/14/2025, the officer exercised 6,500 options at $8.83 and sold 11,815 shares at a $37.65 weighted average and 553 shares at $37.99, executed through multiple trades under a Rule 10b5-1 plan adopted on April 29, 2024. Following these transactions, the officer beneficially owned 28,684 Class A shares directly and 12,500 options remained held. The reported option was fully vested and exercisable.
Kiniksa Pharmaceuticals (KNSA) officer Michael R. Megna reported changes in beneficial ownership on 10/04/2025. The filing shows 175 restricted share units (RSUs) granted (transaction code M) that convert into Class A ordinary shares and vest over four years with 25% vesting each anniversary of the grant date of 10/04/2021. The reporting person also recorded a sale of 85 Class A ordinary shares (transaction code F) at $38.49, leaving 38,101 shares owned after the sale. Following the RSU grant, total beneficial ownership is reported as 38,186 shares. The form was signed by an attorney-in-fact on 10/08/2025.
Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals International plc (KNSA), exercised 42,000 previously granted options at an exercise price of $17.92 on 09/29/2025, acquiring 42,000 Class A ordinary shares. The option is fully vested and exercisable and has an expiration date of 03/03/2029.
The reporting person sold 42,000 Class A ordinary shares the same day under a 10b5-1 trading plan established April 29, 2024, at a weighted-average sales price of $38.33 per share (trades ranged $37.92–$38.85). After these transactions the reporting person beneficially owned 34,552 Class A ordinary shares.
Kiniksa Pharmaceuticals International, plc (KNSA) filing a Form 144 notifies the intended sale of 42,000 Class A ordinary shares on 09/29/2025 through Charles Schwab & Co., Inc. The shares were acquired the same day via an employee stock option exercise and will be sold in a broker-assisted cashless exercise, with the filing reporting an aggregate market value of $1,609,716 against ~43.47 million shares outstanding.
The filing also discloses prior sales by the same holder, Eben Tessari, totaling 303,865 shares sold across seven transactions from 07/14/2025 to 09/15/2025 for aggregate gross proceeds shown per trade. The notice is a required disclosure under Rule 144 and includes the signer’s representation there is no undisclosed material information.
Kiniksa Pharmaceuticals (KNSA) Form 4 — transactions by Eben Tessari. The filing shows transactions on 09/15/2025 executed under a 10b5-1 plan established April 29, 2024. Tessari acquired 6,500 Class A ordinary shares by exercise of options at an $8.83 exercise price and reported ownership of 6,500 underlying shares from that option. On the same date Tessari sold 16,044 Class A shares at a weighted average price of $36.45 and sold 356 Class A shares at a weighted average price of $37. After these transactions reported beneficial ownership counts include 50,952, 34,908, and 34,552 shares respectively. The option involved is described as fully vested and exercisable.
Tessari Eben, Chief Operating Officer and director of Kiniksa Pharmaceuticals International, plc (KNSA), reported exercises of vested share options and subsequent sales on September 4 and 5, 2025 under a 10b5-1 plan. The reporting person exercised a total of 98,660 share options at exercise prices of $15.50 and $15.52, resulting in the acquisition of 98,660 Class A Ordinary Shares. That same week the reporting person sold 98,660 Class A Ordinary Shares in multiple brokered trades at weighted-average prices of about $35.52 and $35.66. After these transactions the reporting person beneficially owned 44,452 Class A Ordinary Shares. The 10b5-1 plan was executed on April 29, 2024, and the Form 4 was signed by an attorney-in-fact on September 8, 2025.
Kiniksa Pharmaceuticals (KNSA) insider sale: Ross Moat, Chief Corporate & Commercial Officer and director, reported a disposition of 3,523 Class A ordinary shares on 09/04/2025 at a price of $35.31 per share. Following the sale, Mr. Moat beneficially owned 9,415 Class A ordinary shares directly. The filing notes the sale was executed pursuant to a 10b5-1 trading plan adopted on November 13, 2024. The Form 4 was signed by an attorney-in-fact on 09/08/2025.